OR WAIT null SECS
August 05, 2024
Video
Strnad explains how findings from the SEQUOIA study inform fazirsiran’s use in patients with AATD-associated liver disease and its further evaluation in future phase 3 trials.
July 30, 2024
Article
Greater circulating Z-polymer levels were associated with an increased risk of adverse clinical outcomes in adults with AATD and the PiZZ genotype.
July 24, 2024
The homogenous genotyping test combines allele-specific tailed primers with SYBR-Green to facilitate fast and accurate detection of PI*S and PI*Z alleles of SERPINA1.
July 10, 2024
Findings from a phase 2b study demonstrate fazirsiran’s dose-dependent impact on Z-AAT concentrations and histological measures of liver disease in patients with AATD.
July 08, 2024
Compared to individuals with the PI*ZZ genotype, those with PI*SS had a lower risk of lung disease, increased lung function, and better quality of life.
June 21, 2024
Although AAT therapy was found to be well-tolerable, the infusions did not improve C-peptide AUC in patients with chronic pancreatitis undergoing TP-IAT.
June 19, 2024
A survey found individuals may avoid participating in AATD trials because a trial may require them to go off augmentation therapy.
June 18, 2024
Findings suggest patients with AATD with liver and/or lung disease face greater all-cause costs and healthcare resource utilization than those with AATD alone.
June 10, 2024
Strnad explains key findings from research presented at the EASL Congress regarding noninvasive testing and biomarkers in AATD-LD based on phase 2 fazirsiran clinical trials.
June 05, 2024
